Gritstone Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Provides Corporate Updates
10 mars 2022 16h05 HE
|
Gritstone bio
-- Four trials now initiated for CORAL, Gritstone’s second-generation COVID-19 program focused on delivering T cell enhanced self-amplifying mRNA (samRNA) vaccines -- -- Oncology programs advancing...
Gritstone Announces Three Presentations for Tumor-Specific Neoantigen (TSNA) Oncology Programs, GRANITE and SLATE, at the 2022 AACR Annual Meeting
08 mars 2022 17h15 HE
|
Gritstone bio
-- Oral presentation to discuss how translational immunology data enabled iterative development of an optimized, KRAS-specific version of “off-the shelf” vaccine candidate; the optimized...
Gritstone to Participate in Cowen 42nd Annual Health Care Conference
24 févr. 2022 07h00 HE
|
Gritstone bio
EMERYVILLE, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease...
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08 févr. 2022 16h05 HE
|
Gritstone bio
EMERYVILLE, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease...
Gritstone to Participate in Precision Oncology Panel at BIO CEO & Investor Conference
08 févr. 2022 07h00 HE
|
Gritstone bio
EMERYVILLE, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease...
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
25 janv. 2022 16h05 HE
|
Gritstone bio
EMERYVILLE, Calif., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease...
Gritstone Announces First Patient Enrolled for Phase 2/3 Trial Evaluating Individualized Neoantigen Vaccine GRANITE for First Line (1L) Maintenance Treatment of Metastatic, Microsatellite-Stable Colorectal Cancer (MSS-CRC)
13 janv. 2022 07h00 HE
|
Gritstone bio
-- Phase 2/3 GRANITE-CRC-1L trial has registrational intent -- -- Updated data from Phase 1/2 trial in end-stage metastatic MSS-CRC further support the association of circulating tumor DNA (ctDNA)...
Gritstone Announces Positive Clinical Results from First Cohort of a Phase 1 Study (CORAL-BOOST) Evaluating a T Cell-Enhanced Self-Amplifying mRNA (samRNA) Vaccine Against COVID-19
04 janv. 2022 07h00 HE
|
Gritstone bio
-- Single 10 µg dose of samRNA vaccine containing Spike plus additional T cell epitopes (TCE) induced robust neutralizing antibody titers in ten healthy adults ≥60yrs who had received two prior doses...
Gritstone Announces Presentations during Three Upcoming Investor Conferences
30 déc. 2021 07h00 HE
|
Gritstone bio
EMERYVILLE, Calif., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease...
Gritstone Announces Changes to Its Board of Directors
17 déc. 2021 07h00 HE
|
Gritstone bio
-- Clare Fisher, accomplished corporate and business development executive and current svp of business development and mergers & acquisitions at BeiGene, will join the Board effective January 1,...